Latest News About Rsv Vaccine Eligibility

Here’s the latest on RSV vaccine eligibility as of mid-2026.

Direct answer

• In the United States, eligibility has been expanding over time to include more adults at risk, with recommendations evolving for high-risk individuals aged 50 and older in certain updates, and ongoing consideration for broader use in 60-74 and 75+ age groups. For UK-specific guidance, eligibility typically follows NHS recommendations and seasonal rollout plans, with priority for older adults and people with certain health conditions. If you’re in London, England, check the NHS RSV vaccination guidance for your age/health status this RSV season.

Key points by region

• United States
  • ACIP/CDC actions in 2024–2025 broadened use for adults 60–74 at high risk and all adults 75+, with later discussions about adding 50–59-year-olds who have qualifying medical conditions or other risk factors. Some vaccines have approvals to cover adults 50–59 at increased risk, depending on FDA labeling and ACIP/CDC final adoption. The vaccines shown in these updates include Pfizer’s ABRYSVO and GSK’s Arexvy; other manufacturers have pursued similar indications. Clinical data indicated substantial reductions in RSV-related hospitalizations among vaccinated older adults. For up-to-date status, consult the CDC’s RSV vaccines page or ACIP meeting summaries.[4][5][6][8]
• United Kingdom
  • The UK’s vaccination guidance is issued by the NHS and Public Health England/England’s health authorities. Eligibility typically targets older adults (often 65+ or 70+ depending on the year) and those at higher risk due to chronic conditions or immunocompromise. Seasonal recommendations may differ from the US, and the rollout is aligned with national vaccination programs. Check NHS RSV vaccine guidance or your GP for current eligibility this season. (No single US-style national update; refer to NHS/UK government sources for the latest lines.) [no direct UK-CDC-like page in these results]

What to do next

• If you’re in London or elsewhere in the UK:
  • Check NHS.UK or your local GP practice for the current RSV vaccine eligibility, as well as how to book. [UK-specific guidance needs official NHS sources]
• If you’re in the US:
  • Review the latest ACIP/CDC recommendations and vaccine labeling for your age group and health status, as eligibility can depend on age bands (50–59, 60–74, 75+) and risk factors. If you have a high-risk condition or live in settings with increased exposure, you’re more likely to be eligible. [CDC/ACIP pages]

Illustrative example

• A 62-year-old with chronic heart disease would typically be considered at higher risk for severe RSV and may be eligible for vaccination under expanded guidelines, depending on the exact current labeling and ACIP/cDC adoption status. Always verify with a clinician or vaccination site.[1][6]

Limitations

• RSV vaccine eligibility is evolving as new data and approvals occur. For the most precise, up-to-date eligibility in your locale, consult official local health authorities (CDC/ACIP in the US; NHS and Public Health England in the UK) or your GP.[5][6]

Citations

• CDC updates and RSV vaccine guidelines for adults, including age-based expansions and risk-factor considerations[6]
• ACIP voting and expanded recommendations for RSV vaccines in adults 50–59 at increased risk, and broader usage context[4]
• CDC coverage and initial recommendations for seniors 60+ and high-risk 60–74 groups[5]
• FDA/ACIP alignment on Pfizer’s ABRYSVO and related vaccine expansions[4]

If you’d like, I can pull the current official UK NHS page and the latest US ACIP/CDC summaries and summarize the precise eligibility for your exact age and health status.